Every material Form 8-K Axalta filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Axalta entered into a sixteenth amendment to its credit agreement on November 26, 2024, lowering the interest rate spread on its term loan from 2.00% to 1.75% over SOFR. The principal amount and maturity date of the term loan are unchanged, so the change reduces borrowing cost without altering the debt's size or repayment schedule.
Term loan spread over SOFR reduced from 2.00% to 1.75%
Outstanding principal amount and maturity date of the term loan unchanged
Amendment No. 16 filed as Exhibit 10.1; certain exhibits omitted under Regulation S-K Item 601(a)(5)
Axalta reported third-quarter 2024 net sales of $1.32 billion, up 0.8% from a year earlier, and net income of $102 million, up 40%. Diluted earnings per share rose 39% to $0.46, and the company also issued full-year 2024 outlook figures for shareholders to track.
Net sales of $1.32 billion were up 0.8% year over year, a third-quarter company record; Adjusted EBITDA rose 12% to $291 million, with a 22.1% margin.
Net income rose 40% to $102 million; diluted EPS was $0.46 versus $0.33, and Adjusted Diluted EPS was $0.59.
Cash provided by operating activities was $194 million versus $210 million a year earlier, driven mainly by higher working capital; the company repurchased $50 million of common shares.
Full-year 2024 outlook includes net sales of about $5,275 million, Adjusted Diluted EPS of $2.15 and Free Cash Flow of about $500 million.
Axalta reported second-quarter 2024 net sales up 4.4% year over year to $1.35 billion, net income up $52 million to $113 million, and diluted EPS of $0.51 versus $0.27 a year earlier. The company raised its full-year 2024 Adjusted EBITDA, Adjusted Diluted EPS and Free Cash Flow guidance, which matters to shareholders because it signals the company expects stronger earnings and cash flow for the year.
Q2 net sales of $1.35 billion, up 4.4%; Adjusted EBITDA of $291 million, a quarterly record, with a 21.5% margin
Diluted EPS of $0.51 versus $0.27; Adjusted Diluted EPS of $0.57, up 63%
Full-year 2024 Adjusted EBITDA projected at about $1,090 million to $1,100 million; Adjusted Diluted EPS about $2.05
Q2 operating cash flow of $114 million; $185 million revolver draw to fund the CoverFlexx acquisition; $50 million of shares repurchased
On June 21, 2024, Axalta and its subsidiaries entered into the Fifteenth Amendment to their Credit Agreement with certain lenders and Barclays Bank PLC as administrative agent. The amendment increases the revolving credit facility from $550 million to $800 million and extends its maturity from May 2026 to June 2029, subject to acceleration in certain circumstances. The filing gives more borrowing capacity and a later maturity date but does not describe the reasons for the change or any borrowings under the facility.
Revolving credit commitments increased from $550 million to $800 million.
Maturity of the revolving credit facility extended from May 2026 to June 2029, subject to acceleration in certain circumstances.
Amendment dated June 21, 2024; Barclays Bank PLC is administrative agent and collateral agent.
Full text filed as Exhibit 10.1 to the 8-K dated June 24, 2024.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Axalta filing is on SEC EDGAR ↗. 8-K briefs of other companies →